Black women are disparately affected by triple-negative breast cancer (TNBC), experiencing higher mortality rates and poorer outcomes than White women, often due to screening delays leading to later-stage diagnoses. Lifting the barriers to access begins with addressing the social determinants of health and distrust of the health care system that prevent many Black women from seeking care. Outcomes improve when health care professionals (HCPs) understand these inequities and include Black women’s perspectives in treatment decisions. When HCPs integrate patient perspectives and preferences and use guideline-driven protocols, they lessen the inequities between Black and White women with TNBC. Engaging Black women throughout the process, from earlier screening to shared treatment decision-making to inclusion in clinical trials, HCPs can meet Black women where they are and move toward better outcomes.
In this CMEO Webcast, expert faculty will discuss the health inequities Black women with TNBC face, in screening, treatment, and outcomes, and how these disparities relate to the social determinants of health. In addition, they will present treatment protocols and guidelines, including the latest agents approved to treat TNBC, to help reduce these inequities. Lastly, faculty will outline how understanding the obstacles and barriers that Black women face can help inform better treatments and outcomes.
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Merck Sharpe & Dohme Corp.
Physicians, PAs, nurse practitioners, nurses, pharmacists and clinical researchers specializing in oncology.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Hurvitz reports the following financial relationships: Consultant/Advisory Board (Uncompensated): 4DPharma plc; Ambrx; Amgen Inc.; Artios Pharma; Arvinas; Biotheranostics; Daiichi Sankyo, Inc.; Dantari; Eli Lilly and Company; Genentech, Inc./Roche; Immunomedics; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; NKMAX Co., Ltd.; Pieris Pharmceuticals, Inc.; Pyxis Oncology; and Seagen Inc. Grants (Paid to UCLA): Ambrx and Samumed, LLC. National/International Principal Investigator: Daiichi Sankyo, Inc.; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation; and Seagen Inc. Research Support (Paid to Institution): Ambrx; Amgen Inc.; AstraZeneca; Arvinas; Bayer AG; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dignitana; Eli Lilly and Company; Genentech, Inc./Roche; Gilead Sciences, Inc.; GlaxoSmithKline; Immunomedics; MacroGenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma; Orinove Inc.; Pfizer Inc.; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc. Steering Committee: Lilly; Daiichi Sankyo, Inc./AstraZeneca; Genentech, Inc./Roche; Novartis Pharmaceuticals Corporation; and Sanofi
Dr Nanda reports the following financial relationships: Advisory Board: AstraZeneca; BeyondSpring Inc.; Cardinal Health; Fujifilm; Immunomedics/Gilead Sciences, Inc.; Infinity. Pharmaceuticals, Inc.; iTeos Therapeutics; MacroGenics, Inc.; Merck & Co., Inc.; OBI Pharma; OncoSec Medical Incorporated; and Seagen Inc. Research Support: Arvinas; AstraZeneca; Celgene Corporation; Corcept Therapeutics; Genentech, Inc./Roche; Immunomedics; Merck & Co., Inc.; OBI Pharma; Odonate Therapeutics, Inc.; OncoSec Medical Incorporated; Pfizer Inc.; Seattle Genetics, Inc.; and Taiho. Oncology, Inc.
Dr. Whitaker reports the following financial relationships: Consultant: Novartis. Grants: The V Foundation for Cancer Research. Research Support: The V Foundation for Cancer Research and National Institutes of Health (NIH). Other Financial or Material Support: Axis Medical Education and Total Health Conferencing
The following peer reviewer and CME Outfitters staff have no financial relationships to disclose:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-21-070-H01-P.
Call us at 877.CME.PROS (877.263.7767).